731 related articles for article (PubMed ID: 29916015)
21. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
[TBL] [Abstract][Full Text] [Related]
22. 3' Splice site sequences of spinal muscular atrophy related SMN2 pre-mRNA include enhancers for nearby exons.
Cho S; Moon H; Loh TJ; Oh HK; Kim HR; Shin MG; Liao DJ; Zhou J; Zheng X; Shen H
ScientificWorldJournal; 2014; 2014():617842. PubMed ID: 24616638
[TBL] [Abstract][Full Text] [Related]
23. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
24. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.
Singh NN; Howell MD; Androphy EJ; Singh RN
Gene Ther; 2017 Sep; 24(9):520-526. PubMed ID: 28485722
[TBL] [Abstract][Full Text] [Related]
25. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
Singh RN; Ottesen EW; Singh NN
Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
[TBL] [Abstract][Full Text] [Related]
26. How RNA structure dictates the usage of a critical exon of spinal muscular atrophy gene.
Singh NN; Singh RN
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194403. PubMed ID: 31323435
[TBL] [Abstract][Full Text] [Related]
27. Nusinersen: The First Option Beyond Supportive Care for Spinal Muscular Atrophy.
Maharshi V; Hasan S
Clin Drug Investig; 2017 Sep; 37(9):807-817. PubMed ID: 28755059
[TBL] [Abstract][Full Text] [Related]
28. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
29. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
30. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2.
Cartegni L; Hastings ML; Calarco JA; de Stanchina E; Krainer AR
Am J Hum Genet; 2006 Jan; 78(1):63-77. PubMed ID: 16385450
[TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotide mediated therapy of spinal muscular atrophy.
Sivanesan S; Howell MD; Didonato CJ; Singh RN
Transl Neurosci; 2013 Mar; 4(1):. PubMed ID: 24265944
[TBL] [Abstract][Full Text] [Related]
32. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
[TBL] [Abstract][Full Text] [Related]
33. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
Zhang ML; Lorson CL; Androphy EJ; Zhou J
Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
[TBL] [Abstract][Full Text] [Related]
34. Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene.
Niba ETE; Nishio H; Wijaya YOS; Lai PS; Tozawa T; Chiyonobu T; Yamadera M; Okamoto K; Awano H; Takeshima Y; Saito T; Shinohara M
Brain Dev; 2021 Feb; 43(2):294-302. PubMed ID: 33036822
[TBL] [Abstract][Full Text] [Related]
35. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.
Osman EY; Yen PF; Lorson CL
Mol Ther; 2012 Jan; 20(1):119-26. PubMed ID: 22031236
[TBL] [Abstract][Full Text] [Related]
36. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy.
Shababi M; Mattis VB; Lorson CL
Drug News Perspect; 2010 Oct; 23(8):475-82. PubMed ID: 21031163
[TBL] [Abstract][Full Text] [Related]
37. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
39. Is RNA manipulation a viable therapy for spinal muscular atrophy?
Horne C; Young PJ
J Neurol Sci; 2009 Dec; 287(1-2):27-31. PubMed ID: 19758605
[TBL] [Abstract][Full Text] [Related]
40. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of
Toosaranont J; Ruschadaariyachat S; Mujchariyakul W; Arora JK; Charoensawan V; Suktitipat B; Palmer TN; Fletcher S; Wilton SD; Mitrpant C
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
